1621673-53-7

基本信息
4-[[([1,1'-Biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)benzamide
Benzamide, 4-[[([1,1'-biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)-
inhibit,anti-diabetic,leptin,ZO-1,LPS,insulin,phosphorylated,KY-226,Akt,KY226,anti-obesity,PTP1B,Phosphatase,neurons,Inhibitor,KY 226
物理化学性质
密度 | 1.186±0.06 g/cm3(Predicted) |
储存条件 | -20° |
溶解度 | 溶于 DMSO (>25 mg/ml)。 |
酸度系数(pKa) | 3.91±0.40(Predicted) |
形态 | 固体 |
颜色 | 米白色 |
稳定性 | 自购买之日起 1 年内保持稳定。 DMSO 中的溶液可在 -20° 下保存长达 3 个月。 |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
抑制剂价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-120327 | 抑制剂 KY-226 | 1621673-53-7 | 1 mg | 920元 |
2025/02/08 | HY-120327 | 抑制剂 KY-226 | 1621673-53-7 | 5mg | 2300元 |
2025/02/08 | HY-120327 | 抑制剂 KY-226 | 1621673-53-7 | 10mM * 1mLin DMSO | 2437元 |
常见问题列表
Target | Value |
PTP1B
(Cell-free assay) | 0.28 μM |
In human hepatoma-derived cells (HepG2), KY-226 (0.3-10 μM) increases the phosphorylated insulin receptor (pIR) produced by insulin.
KY-226 (1 μM; 24 hours; bEnd.3 cells) treatment rescues lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. KY-226 treatment restores phosphorylation of pAkt (T308) and its downstream target forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells.
Western Blot Analysis
Cell Line: | bEnd.3 cells stimulated with LPS |
Concentration: | 1 μM |
Incubation Time: | 24 hours |
Result: | Rescued lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. |
KY-226 (10-30 mg/kg/day; oral administration; daily; for 4 weeks; male
db/db
mice) treatment significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain.
KY-226 attenuates plasma glucose elevations in the oral glucose tolerance test. KY-226 also increases pIR and phosphorylated Akt in the liver and femoral muscle.
Animal Model: | Male db/db mice (8-11 weeks old) |
Dosage: | 10 mg/kg and 30 mg/kg |
Administration: | Oral administration; daily; for 4 weeks |
Result: | Significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain. |